Clinical Trials Logo

High Output Shock clinical trials

View clinical trials related to High Output Shock.

Filter by:
  • None
  • Page 1

NCT ID: NCT03623529 Recruiting - Septic Shock Clinical Trials

A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock

Start date: August 2018
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) as assessed by standard of care vasopressor dose reduction in pediatric patients with catecholamine-resistant hypotension (CRH). In addition, this study will evaluate the safety and tolerability of LJPC-501 in pediatric patients, evaluate changes in catecholamine and other vasopressor doses over time, evaluate the change in MAP over time, and the change in Pediatric Logistic Organ Dysfunction-2 (PELOD-2) scores.

NCT ID: NCT03431077 Completed - Sepsis Clinical Trials

A Study of LJPC‑501 in Pediatric Patients With Hypotension

Start date: February 11, 2018
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial pressure (MAP) or reduction in sum norepinephrine (NE) equivalent dosing, at Hour 2 after the start of LJPC-501, in pediatric patients who remain hypotensive despite receiving fluid therapy and vasopressor therapy. In addition, this study will evaluate the safety and tolerability of LJPC-501 in pediatric patients, the change in MAP over 24 hours after the start of LJPC-501, the change in serum lactate concentrations, and the change in Pediatric Logistic Organ Dysfunction (PELOD) scores.

NCT ID: NCT03245528 Approved for marketing - Sepsis Clinical Trials

Expanded Access for LJPC-501

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.

NCT ID: NCT02338843 Completed - Sepsis Clinical Trials

A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

ATHOS-3
Start date: March 2015
Phase: Phase 3
Study type: Interventional

This is a Phase 3, double-blind, randomized study of LJPC-501 (angiotensin II) in adult patients diagnosed with catecholamine-resistant hypotension (CRH) conducted in multiple centers globally.